Kewaunee Scientific (KEQU) Q2 2026 earnings review
Acquisition Masks Organic Erosion
Kewaunee reported a massive 47% YoY revenue surge to $70.1M, but the numbers are deceptive. The growth is entirely driven by the Nu Aire acquisition (closed Nov 2024). The legacy domestic construction business is shrinking, evidenced by a 19% drop in Net Income and a 20% decline in Domestic segment earnings despite the top-line boom. While International execution is improving, the sequential backlog decline suggests demand normalization is underway.
🐂 Bull Case
The International segment is finally delivering on its backlog. Revenue grew 31% YoY to $14.9M, and segment net earnings nearly doubled (+80%), driven by the execution of large projects booked in prior periods.
Management explicitly stated Nu Aire had a 'strong quarter,' effectively subsidizing the weakness in the legacy laboratory construction business. Without this inorganic contribution, the quarter would have been a significant miss.
🐻 Bear Case
Domestic sales rose 52% (due to Nu Aire), yet Domestic Net Earnings *fell* 20% to $3.6M. This indicates severe negative operating leverage in the legacy construction business, likely due to lower manufacturing volumes and overhead absorption issues.
Order backlog has declined sequentially for two consecutive quarters, dropping from a peak of $214.6M in 25Q4 to $192.9M now. While still high historically, the trajectory indicates the post-pandemic demand wave is receding.
⚖️ Verdict: 🔴
Bearish. The headline revenue growth is 'empty calories' from M&A. The core organic business is suffering from volume declines that are crushing margins. With backlog sliding and project timelines volatile, the earnings quality is deteriorating.
Key Themes
Legacy Business Implosion
The most concerning data point is the Domestic segment profitability. Despite adding Nu Aire's revenue stream ($19M+ delta YoY), segment earnings dropped by nearly $1M. Management attributed this to 'lower manufacturing volumes across the laboratory construction portion.' This implies the high-margin legacy business is contracting faster than the acquisition can compensate.
Backlog Erosion
Backlog is the primary forward-looking indicator for Kewaunee, and the trend has reversed. After peaking at $214.6M in April 2025, it has slipped to $205M in July and now $192.9M in October. A 10% decline in six months suggests book-to-bill is running below 1.0.
International Execution
The International segment has shifted from a drag to a contributor. Sales increased 31% to $14.9M and EBITDA margins expanded from 5.2% to 5.8%. The driver is the 'continued delivery of large projects' booked previously, particularly in India where site delays have resolved.
Project Volatility
Management reiterated guidance for 'volatility in project delivery timelines' for the remainder of FY26. This construction-sector macro headwind makes quarterly earnings lumpy and unpredictable, as customers delay site readiness.
Nu Aire Integration
The Nu Aire acquisition (biosafety cabinets) is performing well operationally, described as having a 'strong quarter.' It provides a necessary buffer against the construction cycle, as these products are equipment-focused rather than project-construction focused.
Other KPIs
Decelerating. Adjusted EBITDA fell 4.4% YoY despite the 47% revenue increase. The margin compressed significantly from 13.4% in 25Q2 to 8.8% in 26Q2, reflecting the lower efficiency in the legacy plant.
Increased from $64.7M at FY25 year-end. The company is carrying higher working capital loads relative to its shrinking organic volume, potentially due to inventory stickiness ($35.5M vs $32.8M).
Stable. Down slightly from $60.7M in April. The leverage ratio remains manageable (Debt-to-Equity 0.88), but the interest expense burden ($1.06M vs $0.44M YoY) is now a meaningful headwind to net income.
Guidance
Stable/Negative. Management expects 'volatility in project delivery timelines' to persist. While quoting activity is 'strong,' the lack of reaffirmed numerical targets alongside the sequential backlog drop implies a softer H2 compared to H1.
Key Questions
Organic Growth Disclosure
With Domestic revenue up 52% but earnings down 20%, can you break out the organic revenue decline in the legacy business versus the Nu Aire contribution?
Backlog Trend
Backlog has declined ~$22M over the last two quarters. Is this purely a function of accelerated project delivery, or are you seeing a slowdown in incoming order rates for laboratory construction?
Manufacturing Overhead
You cited lower manufacturing volumes impacting Domestic profitability. Are you considering capacity rationalization or cost-out measures if legacy volumes do not rebound in H2?
Nu Aire Seasonality
Nu Aire was cited as having a strong quarter. Is there specific seasonality to this product line that we should expect to reverse in Q3 or Q4?